H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

On Friday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $26.03 which represents a decrease of $-0.12 or -0.46% from the prior close of $26.15. The stock opened at $26.15 ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price trimmed by Sanford C. Bernstein from $27.00 to $24 ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the ...

Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...